Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Lee



Author of

  • +

    OA 15 - Diagnostic Radiology, Staging and Screening for Lung Cancer II (ID 684)

    • Event: WCLC 2017
    • Type: Oral
    • Track: Radiology/Staging/Screening
    • Presentations: 1
    • +

      OA 15.08 - Thoroughness of Staging and the Outcomes of Surgical Resection Outcomes in Potentially Curable Non-Small Cell Lung Cancer (NSCLC) (ID 10059)

      15:45 - 15:55  |  Author(s): Y. Lee

      • Abstract
      • Presentation
      • Slides

      Background:
      Substantial variation exists in the processes of care for potentially curable NSCLC. We examined the impact of thoroughness of staging for patients undergoing NSCLC surgery in a large, heterogeneous population within a lung cancer endemic region of the US.

      Method:
      We evaluated all surgically resected patients in the Mid-South Quality of Surgical Resection (MS-QSR) cohort from 2009-2017. MS-QSR is a population-based cohort including all curative-intent NSCLC resections at 11 hospitals in the mid-south US. Patients were classified into 8 groups based on use (Yes/No) of the following staging modalities: PET/CT, pre-operative invasive staging, operative mediastinal nodal examination (MLE). We compared stage distribution, adjuvant therapy, and overall survival outcomes across groups using the chi-square test and adjusted Proportional Hazards Models.

      Result:
      The 2,370 patients had a median age of 67 years, were 53% male. The racial distribution was: 70% White, 25% Black, 5% Other. Clinical N-stage was similar between the 8 groups. We found statistically significant differences in pathologic stage distribution, adjuvant therapy usage, and overall survival across the 8 groups (Table 1). Patients who received PET/CT, invasive staging, and MLE (Group 1) had significantly higher pathologic N-stage distribution compared to the other groups due to substantial nodal upstaging. Group 1 had 76% eligibility and 31% use of adjuvant chemotherapy compared to 51% and 8% in the Group 8 (No PET/CT, No Invasive Staging, No MLE). Use and eligibility for adjuvant radiation therapy was also highest in Group 1. There was an overall difference in survival across the groups (p-value=0.0019) which remained significant after adjusting for age, sex, race, histology, and path stage (p-value=0.0013). After adjustment, Group 8 had a 14% increased hazard of death compared with Group 1. Figure 1



      Conclusion:
      A less thorough approach to staging may lead to less nodal upstaging and less eligibility for adjuvant therapy, which could have implications for long term survival.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.16 - Surgery (ID 717)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Surgery
    • Presentations: 1
    • +

      P2.16-019 - Improving Survival with a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resections (ID 10000)

      09:30 - 09:30  |  Author(s): Y. Lee

      • Abstract
      • Slides

      Background:
      Poor pathologic nodal staging impairs overall survival (OS) after curative-intent surgical resection of NSCLC. We implemented a LN collection kit and previously demonstrated how it improves pathologic nodal staging. We now report its survival impact.

      Method:
      Using a prospective step-wedge design, kits were implemented for curative-intent surgical resections from 2009-2017 in 11 hospitals within 4 contiguous US Dartmouth Hospital Referral Regions. OS was analyzed with the Kaplan-Meier method. Crude (HR) and adjusted (aHR) hazard ratios with 95% confidence intervals (CI) are presented from Proportional Hazards Models adjusted for clustering by surgeon. Covariates in adjusted models include: age, sex, histology, tumor grade, extent of resection, T and M categories, and number of comorbidities.

      Result:
      The LN kit was used in 734 of 2,547 (29%) resections. All demographic and clinical characteristics, including age, sex, race, health insurance coverage and preoperative stage distribution were similar between kit and non-kit cases. Aggregate 1, 3, 5-year OS: 89%, 74%, 66%(kit) vs. 83%, 65%, 53% (non-kit) (p< 0.0001, Fig.1). Clinical stage stratification (kit v non-), 5-year OS: I, 68% vs. 58%, (p-value=0.0038); II, 68% vs. 40%, (p=0.0045); III, 57% vs. 42%, (p=0.0412). Pathologic stage stratification (kit v non-) 5-year OS: I, 72% vs. 59% (p=0.0082), II, 60% vs. 44% (p=0.0403); III, 48% vs. 36%, p =0.0179). For both clinical and pathologic Stage IV, survival did not differ. Kit cases had a 30% lower hazard of death compared to non-kit cases: HR 0.67 (CI[0.55,0.80], p<0.0001) and aHR: 0.70 (CI[0.54,0.92], p<0.0001). Results remained statistically significant after multiple sensitivity analyses excluding sub-lobar resections, 60-day mortality, non-adopting surgeons, and excluding the 48 months of retrospective baseline control data (aHR: 0.28 to 0.73). Operating time, perioperative complication rates, and duration of hospitalization were similar between groups. Figure 1



      Conclusion:
      Intraoperative specimen collection with a LN kit improves long-term NSCLC survival.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.